- Tempest Therapeutics Inc To Discuss Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma Call TranscriptOct 11, 2023
- Tempest Therapeutics Inc at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 15, 2023
- Tempest Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Tempest Therapeutics Inc To Discuss Phase 1b/2 Combination Study of TPST-1120 in First-Line HCC Data Call TranscriptApr 28, 2023
- Tempest Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Tempest Therapeutics Inc Annual Shareholders Meeting TranscriptJun 17, 2022
- Tempest Therapeutics Inc At ASCO Call TranscriptJun 05, 2022
- Millendo Therapeutics Inc And Tempest Therapeutics Inc Merger - M&A Call TranscriptMar 29, 2021
Tempest Therapeutics Inc At ASCO Call Transcript
Good morning, everyone. I'm Steve Brady, I'm the CEO of Tempest Therapeutics. And this morning, I am joined by my colleague, Tom Dubensky, our President; Sam Whiting, our Chief Medical Officer; Anne Moon, who heads up Product and Project Development. And Nick Maestas, hand up, thanks Nick, who is the Vice President of Finance and Strategy. We are really fortunate this morning to be joined by a group of distinguished thought leaders. They're the real reason you're here not to listen to any of the Tempest folks. First, Mark Yarchoan from Hopkins. He's going to be speaking on Tuesday about our lead clinical program, TPST-1120 PPAR-alpha antagonist.
Just note there, this is our first clinical data that Tempest has presented, and then he's going to hand the phone off to Susanna Ulahannan from the University of Oklahoma. She's going to be speaking about our second clinical program, TPST-1495. And then finally, Jason Luke from UPMC is going to -- sorry, University of Pittsburgh School of Medicine is going to be talking about our TREX1
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)